DR. ANKITA MITRA

DR. TANIA RAY (BHADRA)

Abstract

Background: Netarsudil reduces the episcleral venous pressure(EVP). Raised EVP leads to glaucoma in Sturge-Weber syndrome(SWS).

Aim: To evaluate the effectiveness of netarsudil in patients with glaucoma in SWS with uncontrolled IOP on maximally tolerated medical therapy.

Methods: Prospective study. SWS-induced glaucoma patients >18years were treated with netarsudil 0.02% as an adjunct to other topical antiglaucoma agents. Treatment success was defined as IOP reduction meeting a predetermined target with no further requirement of medication or surgery.

Results: 25 eyes were included and 16 (64%) achieved treatment success at first follow-up visit. Mean baseline IOP was 26.16 ± 2.34 mmHg which reduced to 20.44 + 3.12 mmHg at first follow up. In patients who achieved treatment success, mean IOP change was −6.25 mmHg

Conclusions: Netarsudil is effective in lowering IOP for glaucoma in SWS on maximally tolerated medical therapy and can serve as an alternative to filtration or shunt surgery.